Astraveus and NecstGen Partner for Innovative CAR-T Therapy Manufacturing Solutions

Astraveus Partners with NecstGen to Revolutionize CAR-T Manufacturing

In a strategic move to enhance the production of CAR-T therapies, Astraveus SAS, a pioneering company in benchtop cellular manufacturing, has announced its partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen). This collaboration aims to evaluate the effectiveness of Astraveus' innovative Lakhesys Benchtop Cell Factory™ at NecstGen's advanced facility located in Leiden, Netherlands.

The Promise of the Lakhesys Benchtop Cell Factory™

The Lakhesys Benchtop Cell Factory™ is a cutting-edge technology that has the potential to significantly reduce costs and improve efficiency in the manufacturing of CAR-T therapies. By leveraging microfluidic technology, the system can streamline the entire production process, addressing some of the pressing constraints currently faced in cell therapy manufacturing.

Jérémie Laurent, the CEO of Astraveus, expressed enthusiasm about the partnership, stating, "NecstGen and Astraveus share a common passion and determination to deliver next-generation cell and gene therapies with increased accessibility and affordability." His statement emphasizes not only the technological advancement brought by their collaboration but also the commitment to making these therapies available to a broader patient population.

Benefits of the Collaboration

This partnership is set to yield substantial benefits. NecstGen will utilize the Lakhesys technology to produce Lentiviral vectors for Astraveus' internal research and development. This represents an essential step forward, as it demonstrates the capacity for external testing and validation of Astraveus' manufacturing platform in a collaborative environment. The duo strives to deliver effective solutions for CAR-T manufacturing that promise to be simpler, faster, and more cost-effective than traditional methods.

At its core, NecstGen operates from one of Europe's largest life science clusters at the Leiden Bio Science Park, where it supports various academic and industrial therapy developers in translating early-stage research into viable patient treatments. Partnering with such a reputable center provides a strong foundation for shared expertise and knowledge.

Comments from NecstGen's Leadership

Paul Bilars, CEO of NecstGen, remarked, "Astraveus' novel approach to the manufacturing of CAR-T cells represents a breakthrough technology with the ability to transform the industry." This aligns with NecstGen’s commitment to collaborate with leading innovators to enhance therapeutic options for patients.

Astraveus' Commitment to Innovation

Since its inception in 2016, Astraveus has been dedicated to revolutionizing the development and manufacturing of cell therapies. The company began at the Saint-Louis Hospital in Paris, a prominent site for cell therapy research. With its focus on delivering cell therapies of the highest quality at drastically lower costs, Astraveus is positioned to make significant impacts in the biotech field.

The Lakhesys Benchtop Cell Factory™ perfectly embodies this mission, utilizing advanced microfluidic technology to optimize and scale manufacturing from the preclinical phase to commercial production. The potential for substantial cost reduction alongside improved manufacturing throughput presents a compelling case for this partnership.

Future Outlook

As both Astraveus and NecstGen gear up to implement this partnership, the future looks promising for the manufacturing of CAR-T therapies. With the built-in capability for scalability and efficiency, the Lakhesys technology may very well play a pivotal role in redefining the industry standards. By easing some of the key barriers in the production of these groundbreaking treatments, such advancements could lead to increased access and affordability for patients worldwide.

In conclusion, the Astraveus and NecstGen partnership marks an essential collaboration that not only signifies technological evolution but also the commitment to enhancing patient outcomes through innovative solutions in CAR-T therapy manufacturing. This strategic alliance is one to watch as it develops, potentially leading to significant advancements in the field of cell and gene therapies.